Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 15, 2022 - Issue 2
Submit an article Journal homepage
214
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Safety assessment of propranolol for infantile hemangioma: a study in an Asian population

Lu YuDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, ChinaORCID Iconhttps://orcid.org/0000-0003-0169-1459
ORCID Icon,
Li WeiDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Zigang XuDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Bin ZhangDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Xiaofeng HanDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Yujuan SunDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Yuanxiang LiuDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Chen WangDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Lei QiuDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Bingyu XiuDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Rui HeDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
,
Li LiDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, ChinaCorrespondence[email protected]
&
Lin MaDepartment of Dermatology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, ChinaCorrespondence[email protected]
 show all
Pages 237-242 | Received 04 Jul 2021, Accepted 25 Nov 2021, Published online: 31 Dec 2021

References

  • Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168–173.
  • Léauté-Labrèze C, Dumas de La Roque E, Hoeger P, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735–746.
  • Theunissen CI, Smitt JH, van der Horst CM. Propranolol versus corticosteroids: what should be the treatment of choice in infantile hemangiomas? Ann Plast Surg. 2015;74(2):237–241.
  • Oksiuta M, Matuszczak E, Debek W, et al. Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature. J Matern Fetal Neonatal Med. 2016;29(1):64–68.
  • Christine Léaute-Labrèze OB, Degrugillier-Chopinet C, Mazereeuw-Hautier J, et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics. 2016;138(4):e20160353.
  • Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet. 2011;377(9770):1011–1018.
  • Jiang Z, Shen Y. Zhu Futang practice of pediatrics. 8th. China: People’s Medical Publishing House; 2015. p. 1518. Chapter 26, Cardiovascular disease.
  • Jiang Z, Shen Y. Zhu Futang practice of pediatrics. 8th. China: People’s Medical Publishing House; 2015. p. 17–21. Chapter 2, Growth and development.
  • Léauté-Labrèze C, Hubiche T, Boralevi F, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–2651.
  • Hsu TC, Wang JD, Chen CH, et al. Treatment with propranolol for infantile hemangioma in 13 Taiwanese newborns and young infants. Pediatr Neonatol. 2012;53(2):125–132.
  • Lee KC, Bercovitch L. Update on infantile hemangiomas. Semin Perinatol. 2013;37(1):49–58.
  • Zhou HH, Koshakji RP, Silberstein DJ, et al. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American Whites. N Engl J Med. 1989;320(9):565–570.
  • Zhou HH, Shay SD, Wood AJ. Contribution of differences in plasma binding of propranolol to ethnic differences in sensitivity. Comparison between Chinese and Caucasians. Chin Med J (Engl). 1993;106(12):898–902.
  • Maguiness SM, Frieden IJ. Current management of infantile hemangiomas. Semin Cutan Med Surg. 2010;29(2):106–114.
  • Yang H, Hu DL, Shu Q, et al. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies. World J Pediatr. 2019;15(6):546–558.
  • Petrovic J, Trifunovic B, Vukomanovic G, et al. Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. J Dermatolog Treat. 2017;28(6):554–558.
  • Babiak-Choroszczak L, Gizewska-Kacprzak K, Dawid G, et al. Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas. Adv Clin Exp Med. 2019;28(3):375–384.
  • Cushing SL, Boucek RJ, Manning SC, et al. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head Neck Surg. 2011;144(1):78–84.
  • Gwinup GR. Propranolol toxicity presenting with early repolarization, ST segment elevation, and peaked T waves on the ECG. Ann Emerg Med. 1988;17(2):171–174.
  • Starkey E, Shahidullah H. Propranolol for infantile haemangiomas: a review. Arch Dis Child. 2011;96(9):890–893.
  • Holland KE, Frieden IJ, Frommelt PC, et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol. 2010;146(7):775–778.
  • Puttgen KB, Summerer B, Schneider J, et al. Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. Ann Oto Rhinol Laryn. 2013;122(9):550–554.
  • Moyakine AV, Kerstjens JM, Spillekom-van Koulil S, et al. Propranolol treatment of infantile hemangioma (IH) is not associated with developmental risk or growth impairment at age 4 years. J Am Acad Dermatol. 2016;75(1):59–63.
  • Hu L, Zhou B, Huang H, et al. Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. J Dermatol. 2016;43(10):1160–1166.
  • Li X, Yang K, Li H, et al. Propranolol treatment for infantile hemangiomas: short-term adverse effects and follow-up to age two. Biomed Res Int. 2019;2019:2728952.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.